BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3…
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours…